Literature DB >> 21036418

Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis.

Kevin N Christensen1, Christine U Lee, Matthew M Hanley, Nelson Leung, Thomas P Moyer, Mark R Pittelkow.   

Abstract

BACKGROUND: Nephrogenic systemic fibrosis (NSF) is a rare, potentially fatal fibrosing disorder associated with renal insufficiency and gadolinium (Gd)-based contrast exposure. The cause remains unknown. To date, all efforts to investigate skin Gd concentrations in patients with NSF have been performed on paraffin-embedded samples, and Gd deposition has not been correlated with disease activity by a statistically significant analysis.
OBJECTIVE: We sought to: (1) quantify Gd concentration in fresh tissue skin biopsy specimens; (2) quantify and compare synchronous Gd concentration of affected skin and unaffected skin in patients with NSF (n = 13) with a control group (n = 13); and (3) quantify serum Gd.
METHODS: We used inductively coupled plasma mass spectrometry.
RESULTS: In patients with NSF, the mean ratio of paired Gd concentrations of affected skin to unaffected skin was 23.1, ranging from 1.2 to 88.9. Mean serum Gd concentrations in patients with NSF were 4.8 ng/mL, which is more than 10 times the level in control patients. A statistically significant correlation existed between serum and affected skin Gd concentrations (r(2) = .74, P < .0001). LIMITATIONS: Because of the feasibility of this study, the main limitation was the small sample size (n = 13 affected and 13 control).
CONCLUSIONS: Determination of Gd concentrations in fresh skin samples and serum using inductively coupled plasma mass spectrometry demonstrates significant differences in the amounts of Gd in involved versus nonlesional skin of patients with NSF. This supports the role of differential free Gd deposition from Gd-based contrast in the pathogenesis of NSF.
Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036418     DOI: 10.1016/j.jaad.2009.12.044

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  13 in total

Review 1.  Gadolinium retention in the body: what we know and what we can do.

Authors:  Enrico Tedeschi; Ferdinando Caranci; Flavio Giordano; Valentina Angelini; Sirio Cocozza; Arturo Brunetti
Journal:  Radiol Med       Date:  2017-03-30       Impact factor: 3.469

Review 2.  Blood pool contrast agents for venous magnetic resonance imaging.

Authors:  Irai S Oliveira; Sandeep S Hedgire; Weier Li; Suvranu Ganguli; Anand M Prabhakar
Journal:  Cardiovasc Diagn Ther       Date:  2016-12

Review 3.  Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.

Authors:  Einat Blumfield; David W Swenson; Ramesh S Iyer; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2019-03-29

Review 4.  The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis.

Authors:  John P Prybylski; Michael Jay
Journal:  Adv Chronic Kidney Dis       Date:  2017-05       Impact factor: 3.620

5.  Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.

Authors:  Catherine Do; Viktor Drel; Chunyan Tan; Doug Lee; Brent Wagner
Journal:  J Invest Dermatol       Date:  2019-04-09       Impact factor: 8.551

Review 6.  Evaluating the Patient with Reported Gadolinium-Associated Illness.

Authors:  Tatyana Lyapustina; Charlotte Goldfine; Sean Rhyee; Kavita M Babu; Matthew K Griswold
Journal:  J Med Toxicol       Date:  2018-11-29

Review 7.  Gadolinium in Medical Imaging-Usefulness, Toxic Reactions and Possible Countermeasures-A Review.

Authors:  Lennart Blomqvist; Gunnar F Nordberg; Valeria M Nurchi; Jan O Aaseth
Journal:  Biomolecules       Date:  2022-05-24

8.  Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.

Authors:  E Kanal; T J Patton; I Krefting; C Wang
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-27       Impact factor: 3.825

Review 9.  Brain gadolinium deposition after administration of gadolinium-based contrast agents.

Authors:  Tomonori Kanda; Hiroshi Oba; Keiko Toyoda; Kazuhiro Kitajima; Shigeru Furui
Journal:  Jpn J Radiol       Date:  2015-11-25       Impact factor: 2.374

Review 10.  Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.

Authors:  Robert J McDonald; Deborah Levine; Jeffrey Weinreb; Emanuel Kanal; Matthew S Davenport; James H Ellis; Paula M Jacobs; Robert E Lenkinski; Kenneth R Maravilla; Martin R Prince; Howard A Rowley; Michael F Tweedle; Herbert Y Kressel
Journal:  Radiology       Date:  2018-09-11       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.